Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michelle Dees

Psychiatry Chicago, IL Medical Doctor

NPI 1871648642 CMS profile 267006

213 N Morgan St Unit 1D, Chicago, IL 60607

Open in the dashboard

General payments

$288,525

644 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michelle Dees of Chicago, IL is reported in the CMS Open Payments database as having received $288,525 across 644 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $599 32
2024 General $37,340 72
2023 General $51,012 104
2022 General $50,087 96
2021 General $44,335 81
2020 General $32,003 90
2019 General $73,149 169

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michelle Dees
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Michelle Dees were reported at $599. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Michelle Dees Psychiatry median Middle half National median
2019 $73,149 $184 $59–$605 $163
2020 $32,003 $119 $36–$372 $114
2021 $44,335 $143 $43–$576 $132
2022 $50,087 $153 $50–$590 $149
2023 $51,012 $170 $56–$651 $160
2024 $37,340 $179 $57–$673 $164
2025 $599 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. ITI, Inc. $66,314 81 payments
  2. Avanir Pharmaceuticals, Inc. $65,497 99 payments
  3. Otsuka America Pharmaceutical, Inc. $51,024 109 payments
  4. Teva Pharmaceuticals USA, Inc. $46,394 44 payments
  5. Alkermes, Inc. $18,714 32 payments
  6. Allergan Inc. $18,712 87 payments
  7. Sunovion Pharmaceuticals Inc. $10,343 34 payments
  8. AbbVie, Inc. $8,135 71 payments
  9. Janssen Pharmaceuticals, Inc $1,093 31 payments
  10. Neuronetics, Inc. $893 15 payments
  11. Other $1,404 41 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $237,466 135 payments
  2. Travel and Lodging $34,148 167 payments
  3. Food and Beverage $13,704 339 payments
  4. Consulting Fee $3,000 1 payment
  5. Education $207 2 payments
Products named General payments · program years 2019–2025
  1. CAPLYTA $66,293 80 payments
  2. NUEDEXTA pseudobulbar affect (PBA) $65,497 99 payments
  3. AUSTEDO $46,156 40 payments
  4. NUEDEXTA Neurology $41,999 85 payments
  5. VRAYLAR $18,839 91 payments
  6. ARISTADA INITIO $18,692 31 payments
  7. ARISTADA Cns $18,692 31 payments
  8. ARISTADA Cns $18,692 31 payments
  9. ARISTADA Cns $18,653 29 payments
  10. ARISTADA Cns $18,653 29 payments
  11. Other $31,140 230 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

692

Median for Psychiatry: 574

Drug cost

$279,826

Median for Psychiatry: $27,624

Branded share of claims

5.1%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Austedo Deutetrabenazine Brand 23 $272,697
Hydroxyzine Hcl Generic 111 $2,388
Lurasidone Hcl Generic 14 $871
Olanzapine Generic 83 $660
Quetiapine Fumarate Generic 69 $491
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 12 $437
Aripiprazole Generic 49 $383
Mirtazapine Generic 49 $333
Buspirone Hcl Generic 44 $265
Alprazolam Generic 35 $244

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAPLYTA
  • ITI, Inc. $21,228
$21,228 — —
NUEDEXTA
  • Otsuka America Pharmaceutical, Inc. $15,481
$15,481 — —
SPRAVATO
  • Janssen Pharmaceuticals, Inc $256
$256 — —
VRAYLAR
  • AbbVie, Inc. $196
$196 — —
Dyanavel XR
  • Tris Pharma Inc $37
$37 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

644 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record